A French pharmaceutical company is interested to enrich its portfolio with early stage as well as preclinical or clinical candidates on autoimmune and immuno-inflammatory diseases. The company desires to engage in joint development, in-licensing or asset purchase partnerships and is primary interested by diseases such as Lupus, Primary Sjögren's syndrome and Systemic Sclerosis, and also by other autoimmune or chronic inflammatory diseases.
This French international and independent pharmaceutical company, governed by a non-profit foundation, is focused on developing new therapies for unmet medical needs.As the 2nd French pharmaceutical company and the 30th worldwide, with 3 research centers and 16 production sites this French company has a global reach. With 33 drug candidates in clinical development, they are specialized in 5 major axes: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases and neuropsychiatric diseases.
In the field of immuno-inflammatory and auto-immune diseases, the company is eager to establish new contacts and mid-to-long term partnerships with financial support helping partners to transform innovative projects into patient benefit. Besides extensive research facilities, they also have full capabilities to conduct clinical studies and to help get a new product marketed. The partnerships with projects are flexible in the deal structure: joint development, in-licensing or asset purchase.
The first priorities are projects regarding Lupus, Sjögren's Syndrome, Systemic Sclerosis or any autoimmune or chronic inflammatory disease with related mechanisms. The targets are Th1/Th17 downregulation, Treg upregulation, stimulation of resolution phase of inflammation, any innovative pathway in our targeted diseases. The therapeutic strategies promoted are peptides, antibodies, small molecules, gene therapy, cell therapy and such. Excluded are diagnostics technics (biomarkers), vaccines, services, e-health and medical device.
The projects can be from late exploratory target or pathway partly validated - with evidence from disease-relevant models to target to hit - to preclinical and clinical candidates. Projects from late exploratory (validated targets) to clinical phase II in the scope of resolution phase are included.
- Type of partner sought: The company is looking for new assets for the extension of its portfolio in chronic inflammatory diseases with similar physiopathological mechanisms:
? Downregulation of Th1 and/or Th17 immune responses;
? Upregulation of regulatory responses;
? Stimulation of resolution phase.
The prerequisites for project validation are:
? Target rational (in vitro and/or in vivo);
? Evidence for translation to humans (target/pathway modulation under disease conditions and/or genetic);
? Evidence for target drug-ability and establishing of a robust compound testing flow-scheme;
? Rationale for differentiation to marketed drugs;
? Safety related to target/pathway modulation- Integrin extracellular ligands: collagen, elastin, polylysine, fibronectin, laminin, nidogens, osteopontin.
- Specific area of activity of the partner: The French company is looking for academic or industrial partners. The size of the industrial partner is not important, it can be a startup or a mid-size company.
The company is open to establish mid-to-long term partnerships with financial support. The type of partnership sought can be joint development, in-licensing or asset purchase.
The therapeutic strategies promoted are peptides, antibodies, small molecules, gene therapy, cell therapy and such. Excluded are diagnostics technics (biomarkers), vaccines, services, e-health and medical device.
27 days ago - Are you prepared for Brexit?
32 days ago - Innovate UK's Smart programme
04/06/2019 - Future of Building 2019